Madrigal RGL, Vargas ZR, Carazo BG, Ramírez AN

Language: Spanish
References: 10
Page: 168-183
PDF size: 986.14 Kb.

ABSTRACT

Introduction: clopidogrel bisulphate exists in many crystalline forms that vary in their physicochemical stability: some of these forms either patented or not are useful in the drug production.
Objective: to identify the existing crystalline forms in two samples of Clopidogrel bisufhate raw material for the drug and the purity index of both samples.
Methods: the raw material samples were taken from a domestic industry. They were tested through advanced analytical techniques such as differential scanning calorimetry, X-ray scattering pattern, infrared spectroscopy and thermogravimetric analysis. The final values were then compared with the well-established state-ofthe- art values found in the reviewed literature for the clopidrogrel bisulfate raw materials and accepted as reference.
Results: the physicochemical parameters were obtained from the absorption spectra, thermograms and diffractograms. The TA Universal Analysis software yielded the percentage of decomposition, the melting points and the peak identifiers in the samples.
Conclusions: its was concluded that the sample 1 contained the crystal form I of the Clopridogrel bisulfate that is not a pure one since there is a characteristic band indicating contamination with the crystalline form II. The sample 2 had the pure crystalline form II of the product.

REFERENCES

1. Madrigal G. Análisis de los criterios de expertos sobre los posibles efectos socioeconómicos del fenómeno de polimorfismo de sustancias medicamentosas en materia de patentes de invención en Costa Rica y su aplicación para la sistematización de la vigilancia tecnológica de la industria farmacéutica local. Revista Ciencias Biológicas CNIC [Internet]. 2010 [citado 5 Feb 2012];41(No. Especial). Disponible en http://revista.cnic.edu.cu/revistaCB/files/CB-2010-4-CB-075.pdf

2. Brunton L, Lazo J, Keith P. Goodman y Gillman. Las bases farmacológicas de la terapéutica. 16a ed. México, DF: McGraww Hill; 1996.

3. Suciati ML, Indrayanto G, Brittain HG. Profiles of Drug Substances,Excipients, and Related Methodology. California: Elsevier; 2010.

4. Ministerio de Salud de Costa Rica. Lista de productos que requieren estudios de bioequivalencia in vivo, y perfiles de disolución in vitro para comprobar su equivalencia terapéutica. [citado 19 Oct 2004]. Disponible en: http://www.ministeriodesalud.go.cr/empresas/bioequivalencia/principiosactivosseccion1.pdf

5. Koradia V, Chawla G, Bansal AK. Qualitative and quantitative analysis of clopidogrel bisulphate polymorphs. Acta Pharm. 2004;54:193-204.

6. Bousquet A, Castro B, Saint-Germain J. Nuevo polimorfo de hidrogenosulfato de clopidogrel. Patente de España No. 2 181 439. 2003.

7. Sisteron AB, Castro B, Bicetre K, Germain JS. Polymorphic clopidogrel hydrogenesulphate form. United States patent US 6 429 210. 2002.

8. Radjakrishnan TV, Govind SD, Digambar SK, Madhukarrao DM, Anil MT. Rapid resolution process for clopidogrel base and a process for preparation of clopidogrel bisulfate polymorph-form. India patent No. WO 2006/087729. 2006.

9. Guy BD, Joseph PD, James OM, James PJ, John PW. Novel prostaglandin synthase inhibitors. Esrados Unid patent No. WO 96/10012. 1996.

10. Lohray BB, Lohray VB, Pandey B, Dave MG. Polymorphs and amorphous form of (s)-(+)-clopidogrel bisulfate. United States patent US 2007/0037842. 2007.